The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911

Latest Cancer News

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (10-6-2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (10-1-2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (09-30-2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although... Continue Reading

Intraperitoneal Chemotherapy Underused in Ovarian Cancer (09-28-2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the... Continue Reading

Zelboraf® Active in Hairy Cell Leukemia (09-24-2015)

The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published... Continue Reading

Iressa® Approved as Initial Therapy for Lung Cancer (09-23-2015)

The targeted agent Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration (FDA) as initial therapy in the treatment of patients with advanced lung cancer. Specifically, Iressa was approved as initial therapy for the treatment of... Continue Reading

Gilotrif Improves Outcomes in Lung Cancer (09-22-2015)

The targeted agent Gilotrif (afatinib) improves outcomes compared to Tarceva (erlotinib) among patients with squamous cell lung cancer. These results were recently published in The Lancet Oncology. Lung cancer remains the leading cause of cancer-related... Continue Reading

Daratumumab Effective in Multiple Myeloma (09-17-2015)

The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently published in the New England Journal of Medicine. Multiple... Continue Reading

A Vegan or Vegetarian Diet May Help Improve Treatment of Triple-Negative Breast Cancer (09-16-2015)

Early research suggests that a vegan or vegetarian diet low in the amino acid methionine may help improve treatment of triple-negative breast cancers. These findings were reported in the journal Clinical Cancer Research. The majority of breast cancers... Continue Reading

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer (09-15-2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are... Continue Reading

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer (09-14-2015)

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously untreated lung cancer, researchers said on Monday... Continue Reading

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer (09-10-2015)

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies... Continue Reading

Next Page »